Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease

被引:58
|
作者
Sjodin, Simon [1 ,2 ]
Brinkmalm, Gunnar [1 ,2 ]
Ohrfelt, Annika [1 ,2 ]
Parnetti, Lucilla [3 ]
Paciotti, Silvia [4 ,5 ]
Hansson, Oskar [6 ,7 ]
Hardy, John [8 ,9 ]
Blennow, Kaj [1 ,2 ]
Zetterberg, Henrik [1 ,2 ,8 ,9 ]
Brinkmalm, Ann [1 ,2 ]
机构
[1] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, House V3, SE-43180 Molndal, Sweden
[2] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden
[3] Univ Perugia, Lab Clin Neurochem, Neurol Clin, Perugia, Italy
[4] Univ Perugia, Dept Expt Med, Perugia, Italy
[5] Univ Perugia, Dept Med, Lab Clin Neurochem, Perugia, Italy
[6] Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Lund, Sweden
[7] Skane Univ Hosp, Memory Clin, Malmo, Sweden
[8] UCL, Dept Mol Neurosci, Inst Neurol, Queen Sq, London, England
[9] UCL, UK Dementia Res Inst, London, England
基金
欧洲研究理事会; 瑞典研究理事会;
关键词
Alzheimer's disease; Biomarker; CSF; Mass spectrometry; Parkinson's disease; CEREBROSPINAL-FLUID BIOMARKERS; CHAPERONE-MEDIATED AUTOPHAGY; MILD COGNITIVE IMPAIRMENT; BETA-GLUCOCEREBROSIDASE ACTIVITY; PAIRED HELICAL FILAMENTS; ALPHA-SYNUCLEIN; APOLIPOPROTEIN-E; NEUROFIBRILLARY TANGLES; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES;
D O I
10.1186/s13195-019-0533-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Increasing evidence implicates dysfunctional proteostasis and the involvement of the autophagic and endo-lysosomal system and the ubiquitin-proteasome system in neurodegenerative diseases. In Alzheimer's disease (AD), there is an accumulation of autophagic vacuoles within the neurons. In Parkinson's disease (PD), susceptibility has been linked to genes encoding proteins involved in autophagy and lysosomal function, as well as mutations causing lysosomal disorders. Furthermore, both diseases are characterized by the accumulation of protein aggregates. Methods Proteins associated with endocytosis, lysosomal function, and the ubiquitin-proteasome system were identified in the cerebrospinal fluid (CSF) and targeted by combining solid-phase extraction and parallel reaction monitoring mass spectrometry. In total, 50 peptides from 18 proteins were quantified in three cross-sectional cohorts including AD (N = 61), PD (N = 21), prodromal AD (N = 10), stable mild cognitive impairment (N = 15), and controls (N = 68). Results A pilot study, including subjects selected based on their AD CSF core biomarker concentrations, showed increased concentrations of several targeted proteins in subjects with core biomarker levels indicating AD pathology compared to controls. Next, in a clinically characterized cohort, lower concentrations in CSF of proteins in PD were found compared to subjects with prodromal AD. Further investigation in an additional clinical study again revealed lower concentrations in CSF of proteins in PD compared to controls and AD. Conclusion In summary, significantly different peptide CSF concentrations were identified from proteins AP2B1, C9, CTSB, CTSF, GM2A, LAMP1, LAMP2, TCN2, and ubiquitin. Proteins found to have altered concentrations in more than one study were AP2B1, CTSB, CTSF, GM2A, LAMP2, and ubiquitin. Interestingly, given the genetic implication of lysosomal function in PD, we did identify the CSF concentrations of CTSB, CTSF, GM2A, and LAMP2 to be altered. However, we also found differences in proteins associated with endocytosis (AP2B1) and the ubiquitin-proteasome system (ubiquitin). No difference in any peptide CSF concentration was found in clinically characterized subjects with AD compared to controls. In conclusion, CSF analyses of subjects with PD suggest a general lysosomal dysfunction, which resonates well with recent genetic findings, while such changes are minor or absent in AD.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways
    Majd, Shohreh
    Power, John H.
    Grantham, Hugh J. M.
    BMC NEUROSCIENCE, 2015, 16
  • [22] Key Peptides and Proteins in Alzheimer's Disease
    Penke, Botond
    Bogar, Ferenc
    Paragi, Gabor
    Gera, Janos
    Fulop, Livia
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2019, 20 (06) : 577 - 599
  • [23] CSF in Alzheimer's Disease
    Zetterberg, Henrik
    Lautner, Ronald
    Skillback, Tobias
    Rosen, Christoffer
    Shahim, Pashtun
    Mattsson, Niklas
    Blennow, Kaj
    ADVANCES IN CLINICAL CHEMISTRY, VOL 65, 2014, 65 : 143 - 172
  • [24] Update on CSF Biomarkers in Parkinson's Disease
    Kwon, Eun Hae
    Tennagels, Sabrina
    Gold, Ralf
    Gerwert, Klaus
    Beyer, Leon
    Toenges, Lars
    BIOMOLECULES, 2022, 12 (02)
  • [25] Are Parkinson's Disease Patients the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?
    Tropea, Thomas F.
    Chen-Plotkin, Alice
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [26] CSF and blood biomarkers for Parkinson's disease
    Parnetti, Lucilla
    Gaetani, Lorenzo
    Eusebi, Paolo
    Paciotti, Silvia
    Hansson, Oskar
    El-Agnaf, Omar
    Mollenhauer, Brit
    Blennow, Kaj
    Calabresi, Paolo
    LANCET NEUROLOGY, 2019, 18 (06) : 573 - 586
  • [27] Role of epigenetics in Alzheimer's and Parkinson's disease
    Kwok, John B. J.
    EPIGENOMICS, 2010, 2 (05) : 671 - 682
  • [28] Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
    Sjodin, Simon
    Hansson, Oskar
    Ohrfelt, Annika
    Brinkmalm, Gunnar
    Zetterberg, Henrik
    Brinkmalm, Ann
    Blennow, Kaj
    PROTEOMICS CLINICAL APPLICATIONS, 2017, 11 (11-12)
  • [29] Metabolomics in Alzheimer's disease research
    Ibanez, Clara
    Simo, Carolina
    Cifuentes, Alejandro
    ELECTROPHORESIS, 2013, 34 (19) : 2799 - 2811
  • [30] Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers
    Perneczky, Robert
    Alexopoulos, Panagiotis
    Kurz, Alexander
    TRENDS IN MOLECULAR MEDICINE, 2014, 20 (01) : 8 - 15